Novartis remibrutinib beats teriflunomide in two Phase 3 multiple sclerosis trials
Novartis says oral BTK inhibitor remibrutinib significantly reduced relapse rates and MRI lesions versus teriflunomide in both Phase 3 REMODEL trials, with no liver safety signal and global regulatory filings now planned.